Online inquiry

IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3485MR)

This product GTTS-WQ3485MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets pcrV gene. The antibody can be applied in Pseudomonas aeruginosa infections research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3485MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5359MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ1331MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ8932MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ10521MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ12612MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ9798MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ7495MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ6842MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DT-IL-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW